Ki-67 Expression in CRC Lymph Node Metastasis Does Not Predict Survival

Author:

Martins Sandra F.123,Amorim Ricardo12,Mota Sílvia Coelho1,Costa Luís1,Pardal Fernando4,Rodrigues Mesquita5,Longatto-Filho Adhemar1267

Affiliation:

1. Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus of Gualtar, 4710-057 Braga, Portugal

2. ICVS/3B’s-PT Government Associate Laboratory, Braga/Guimarães, Campus of Gualtar, 4710-057 Braga, Portugal

3. Surgery Department, Hospitalar Center Trás-os-Montes e Alto Douro, Unidade Hospitalar de Chaves, Avenida Dr. Francisco Sá Carneiro, 5400-279 Chaves, Portugal

4. Pathology Department, Braga Hospital, Sete Fontes, São Victor, 4710-243 Braga, Portugal

5. Coloproctology Unit, Braga Hospital, Sete Fontes, São Victor, 4710-243 Braga, Portugal

6. Laboratory of Medical Investigation (LIM) 14, Faculty of Medicine, University of Sao Paulo, 01246-903 São Paulo, SP, Brazil

7. Molecular Oncology Research Centre, 14784-400 Barretos, SP, Brazil

Abstract

Colorectal cancer is one of the most common malignancies and a leading cause of cancer death worldwide. Molecular markers may improve clinicopathologic staging and provide a basis to guide novel therapeutic strategies which target specific tumour-associated molecules according to individual tumour biology; however, so far, no ideal molecular marker has been found to predict disease progression. We tested Ki-67 proliferation marker in primary and lymph node metastasis of CRC. We observed a statistical significant difference between the positive rates of neoplastic cells positively stained by Ki-67 in both sites, with remarkable increased number of Ki-67 positive cells in primary tumor cells compared to cancer cells that invaded lymph nodes. We can speculate that the metastatic CRC in lymph node can be more resistant to the drugs that target cellular division.

Publisher

Hindawi Limited

Subject

General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3